Kristian Brock
Kristian Brock
UCB Pharmaceutical, & Cancer Research UK Clinical Trials Unit, University of Birmingham
Verified email at bham.ac.uk - Homepage
Title
Cited by
Cited by
Year
Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study
P Hillmen, AC Rawstron, K Brock, S Muņoz-Vicente, FJ Yates, R Bishop, ...
Journal of Clinical Oncology 37 (30), 2722-+, 2019
562019
Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication …
P Hillmen, T Munir, A Rawstron, K Brock, S Munoz Vicente, F Yates, ...
Blood 130 (Supplement 1), 428-428, 2017
432017
1384PD Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial
G Middleton, K Brock, Y Summers, J Connibear, R Shah, C Ottensmeier, ...
Annals of Oncology 29 (suppl_8), mdy292. 007, 2018
282018
Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the bloodwise TAP clarity study
P Hillmen, A Rawstron, K Brock, S Munoz Vicente, F Yates, R Bishop, ...
Blood 132 (Supplement 1), 182-182, 2018
272018
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
C Craddock, D Slade, C De Santo, R Wheat, P Ferguson, A Hodgkinson, ...
232019
How to design a dose-finding study using the continual reassessment method
GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ...
BMC medical research methodology 19 (1), 1-15, 2019
162019
Implementing the EffTox dose-finding design in the Matchpoint trial
K Brock, L Billingham, M Copland, S Siddique, M Sirovica, C Yap
BMC medical research methodology 17 (1), 112, 2017
142017
Sustained release of decorin to the surface of the eye enables scarless corneal regeneration
LJ Hill, RJA Moakes, C Vareechon, G Butt, A Ng, K Brock, G Chouhan, ...
NPJ Regenerative medicine 3 (1), 1-12, 2018
112018
Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up
AC Rawstron, D Howard, L McParland, RM de Tute, L Collett, D Phillips, ...
Blood, The Journal of the American Society of Hematology 128 (22), 3226-3226, 2016
102016
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
G Middleton, K Brock, J Savage, R Mant, Y Summers, J Connibear, ...
The Lancet Respiratory Medicine, 2020
92020
The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of …
P Hillmen, A Rawstron, T Munir, K Brock, S Vincente, Y Jefferson, ...
82017
FLAG-IDA and ponatinib in patients with blast phase chronic myeloid leukaemia: results from the phase I/II UK trials acceleration programme matchpoint trial
M Copland, D Slade, J Byrne, K Brock, H De Lavallade, C Craddock, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
62019
Recommendations for randomised trials in surgical oncology
JC Glasbey, EL Magill, K Brock, SP Bach
Clinical Oncology 29 (12), 799-810, 2017
62017
Violet-blue light arrays at 405 nanometers exert enhanced antimicrobial activity for photodisinfection of monomicrobial nosocomial biofilms
FD Halstead, MA Hadis, N Marley, K Brock, MR Milward, PR Cooper, ...
Applied and environmental microbiology 85 (21), 2019
32019
Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with> 1 year prior ibrutinib exposure
A Rawstron, T Munir, K Brock, N Webster, M Vicente, F Yates, S Cramp, ...
32018
Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple …
G Cook, CR Carter, K Brock, G McQuaker, JA Snowden, C Crawley, ...
Blood, The Journal of the American Society of Hematology 128 (22), 4585-4585, 2016
32016
A phase II clinical trial design for associated co-primary efficacy and toxicity outcomes with baseline covariates
K Brock, L Billingham, C Yap, G Middleton
International Conference on Bayesian Statistics in Action, 125-133, 2018
22018
Methods to increase efficiency in clinical trials with restricted sample size
K Brock
University of Birmingham, 2019
12019
Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication …
T Munir, A Rawstron, K Brock, S Vicente, F Yates, R Bishop, C Fegan, ...
12018
Adding obinutuzumab to ibrutinib enhances depletion of CLL cells in peripheral blood and bone marrow after 1 & 6 months combined therapy initial results from the Bloodwise TAP …
A Rawstron, T Munir, S Munoz-Vicente, K Brock, F Yates, R Bishop, ...
12017
The system can't perform the operation now. Try again later.
Articles 1–20